149 related articles for article (PubMed ID: 12952258)
21. Bioequivalence of a Liquid Formulation of Alpha
Barker AF; Campos MA; Brantly ML; Stocks JM; Sandhaus RA; Lee D; Steinmann K; Lin J; Sorrells S
COPD; 2017 Dec; 14(6):590-596. PubMed ID: 28985109
[TBL] [Abstract][Full Text] [Related]
22. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
Campos MA; Lascano J
Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
[TBL] [Abstract][Full Text] [Related]
23. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers.
Vogelmeier C; Kirlath I; Warrington S; Banik N; Ulbrich E; Du Bois RM
Am J Respir Crit Care Med; 1997 Feb; 155(2):536-41. PubMed ID: 9032191
[TBL] [Abstract][Full Text] [Related]
24. Biochemical comparison of four commercially available human α
Boerema DJ; An B; Gandhi RP; Papineau R; Regnier E; Wilder A; Molitor A; Tang AP; Kee SM
Biologicals; 2017 Nov; 50():63-72. PubMed ID: 28882403
[TBL] [Abstract][Full Text] [Related]
25. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR
Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482
[TBL] [Abstract][Full Text] [Related]
26. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency.
Leung K; Louca E; Coates AL
Chest; 2004 Nov; 126(5):1619-27. PubMed ID: 15539736
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency.
Barker AF; Iwata-Morgan I; Oveson L; Roussel R
Chest; 1997 Sep; 112(3):607-13. PubMed ID: 9315791
[TBL] [Abstract][Full Text] [Related]
28. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
Nita I; Hollander C; Westin U; Janciauskiene SM
Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
[TBL] [Abstract][Full Text] [Related]
29. Comment: comparisons of Aralast and Prolastin, alpha1-protease inhibitors for treatment of alpha1-antitrypsin deficiency.
Petteway SR
Ann Pharmacother; 2006 Feb; 40(2):353-4; author reply 354. PubMed ID: 16449545
[No Abstract] [Full Text] [Related]
30. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.
Griese M; Latzin P; Kappler M; Weckerle K; Heinzlmaier T; Bernhardt T; Hartl D
Eur Respir J; 2007 Feb; 29(2):240-50. PubMed ID: 17050563
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Stocks JM; Brantly ML; Wang-Smith L; Campos MA; Chapman KR; Kueppers F; Sandhaus RA; Strange C; Turino G
BMC Clin Pharmacol; 2010 Sep; 10():13. PubMed ID: 20920295
[TBL] [Abstract][Full Text] [Related]
32. Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis.
Byrne NM; Keavey PM; Perry JD; Gould FK; Spencer DA
Arch Dis Child; 2003 Aug; 88(8):715-8. PubMed ID: 12876172
[TBL] [Abstract][Full Text] [Related]
33. Alpha 1-antitrypsin deficiency and the impact of nursing interventions and treatment with intravenous therapy. An overview.
Scharnweber K
J Intraven Nurs; 1999; 22(5):258-64. PubMed ID: 10776189
[TBL] [Abstract][Full Text] [Related]
34. Alpha-1 antitrypsin deficiency, SZ phenotype: a rare type of a rare disease. Case report.
Nebunoiu AM; Deleanu OC; Rohan I; Mihălţan F; Chorostowska-Wynimko J; Ulmeanu R
Pneumologia; 2014; 63(4):218-23. PubMed ID: 25665366
[TBL] [Abstract][Full Text] [Related]
35. [Expert statement for augmentation therapy in patients with alpha-1 antitrypsin deficiency].
Köhnlein T; Schmidt-Scherzer K; Greulich T; Bals R
Pneumologie; 2014 Jul; 68(7):492-5. PubMed ID: 25006842
[TBL] [Abstract][Full Text] [Related]
36. α1-Antitrypsin Deficiency.
Hatipoğlu U; Stoller JK
Clin Chest Med; 2016 Sep; 37(3):487-504. PubMed ID: 27514595
[TBL] [Abstract][Full Text] [Related]
37. Safety of biweekly α
Greulich T; Chlumsky J; Wencker M; Vit O; Fries M; Chung T; Shebl A; Vogelmeier C; Chapman KR; McElvaney NG;
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30237305
[TBL] [Abstract][Full Text] [Related]
38. Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency.
Blanco I; Canto H; de Serres FJ; Fernandez-Bustillo E; Rodríguez MC
J Rheumatol; 2004 Oct; 31(10):2082-5. PubMed ID: 15468381
[TBL] [Abstract][Full Text] [Related]
39. Alpha1-antitrypsin augmentation therapy.
Pierce JA
Chest; 1997 Oct; 112(4):872-4. PubMed ID: 9377947
[No Abstract] [Full Text] [Related]
40. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
